At the first “Dagoku New Drug” global conference held from July 22 to 24, Peng Wei, deputy general manager of Guangzhou Pharmaceutical Group, invited the global high-quality research BD pipeline cooperation project. He said that Guangzhou Pharmaceutical Group is actively constructing a “self-development+merger and acquisition” two-wheel drive pattern. During the “15th Five-Year Plan” period, it plans to invest 20 billion yuan in R&D and 30 billion yuan in industrial mergers and acquisitions and pipeline cooperation, striving to achieve results in mergers and acquisitions within 1-2 years, the merger and acquisition pipeline will bear fruit within 5 to 10 years.

At the first “Dagoku New Drug” global conference held from July 22 to 24, Peng Wei, deputy general manager of Guangzhou Pharmaceutical Group, invited the global high-quality research BD pipeline cooperation project. He said that Guangzhou Pharmaceutical Group is actively constructing a “self-development+merger and acquisition” two-wheel drive pattern. During the “15th Five-Year Plan” period, it plans to invest 20 billion yuan in R&D and 30 billion yuan in industrial mergers and acquisitions and pipeline cooperation, striving to achieve results in mergers and acquisitions within 1-2 years, the merger and acquisition pipeline will bear fruit within 5 to 10 years.